Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin

Annals of Pharmacotherapy

Volumn 43, Issue 9, 2009, Pages 1405-1412

  Ten Berg, Maarten J ^a,b   Van Den Bemt, Patricia M L A ^a,c   Huisman, Albert ^b   Schobben, Alfred F A M ^a,b   Egberts, Toine C G ^a,b   Van Solinge, Wouter W ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Compliance; Heparin induced thrombocytopenia; Low molecular weight heparin; Monitoring; Patient safety

Indexed keywords

DALTEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ADULT; ANTICOAGULATION; ARTICLE; BIOLOGICAL MONITORING; CLINICAL ASSESSMENT; COMPLIANCE (PHYSICAL); FEMALE; HEMODYNAMIC MONITORING; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SURGICAL PATIENT; THROMBOCYTE COUNT;

ADULT; AGED; ANTICOAGULANTS; COHORT STUDIES; DALTEPARIN; DATABASES, FACTUAL; DRUG MONITORING; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; NADROPARIN; PLATELET COUNT; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 69949110647     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L646     Document Type: Article

References (31)

1. Pirmohamed M, Ferner RE. Monitoring drug treatment. BMJ 2003;327:1179-1181
2. European Commission Enterprise and Industry Directorate-General. A guideline on summary of product characteristics. October 2005. ec.europa. eu/enterprise/pharmaceuticals/eudralex/vol-2/c/spcguidrev1-oct2005.pdf (accessed 2008 Dec 23).
3. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006;355:809-817
4. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998;35(4 suppl 5):9-16; discussion 35-36
5. Summary of product characteristics. Heparin (Heparine Leo). Breda, Netherlands: Leo Pharma BV, April 2008.
6. Summary of product characteristics. Dalteparin (Fragmin). Woerden, Netherlands: Pharmacia, May 2002.
7. Summary of product characteristics. Nadroparine (Fraxiparine). Zeist, Netherlands: GlaxoSmithKline, March 2003.
8. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002;126:1415-1423
9. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):311S-37S. (Pubitemid 39297959)
10. Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol 2006;133:259-269
11. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(6 suppl):340S-80S. (Pubitemid 351892970)
12. ten Berg MJ, Huisman A, van den Bemt PM, Schobben AF, Egberts AC, van Solinge WW. Linking laboratory and medication data: new opportunities for pharmacoepidemiological research. Clin Chem Lab Med 2007;45:13-19
13. Greinacher A, Farner B, Kroll H, Kohlmann T,Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005;94:132-135
14. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003;163:2518-2524 (Pubitemid 37385796)
15. Meyer O, Salama A, Pittet N, Schwind P. Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID -HPF4). Lancet 1999;354:1525-1526 (Pubitemid 29502110)
16. Summary of product characteristics. Danaparoid (Orgaran) Oss, Netherlands: Organon, February 2006.
17. Schiff GD, Klass D, Peterson J, Shah G, Bates DW. Linking laboratory and pharmacy: opportunities for reducing errors and improving care. Arch Intern Med 2003;163:893-900. (Pubitemid 36519735)
18. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006;15:369-386
19. Lasser KE, Seger DL, Yu DT, et al. Adherence to black box warnings for prescription medications in outpatients. Arch Intern Med 2006;166:338-344
20. Derijks HJ, De Koning GH, Mantel-Teeuwisse AK, Egberts AC. Limited adherence to safety instructions in drug leaflets. Br J Clin Pharmacol 2002;54:678-679
21. Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002;162:434-437 (Pubitemid 34150645)
22. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med 2001;161:53-58
23. Raebel MA, McClure DL, Simon SR, et al. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf 2006;16:55-64.
24. Raebel MA, Lyons EE, Andrade SE, et al. Laboratory monitoring of drugs at initiation of therapy in ambulatory care. J Gen Intern Med 2005;20:1120-1126 (Pubitemid 43110262)
25. Iezzoni LI. Using administrative diagnostic data to assess the quality of hospital care. Pitfalls and potential of ICD -9-CM. Int J Technol Assess Health Care 1990;6:272-281
26. Prandoni P, Siragusa S, Girolami B, Fabris F. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005;106:3049-3054 (Pubitemid 41565898)
27. Seligman PJ. Thinking outside the (black) box: a new research agenda. Pharmacoepidemiol Drug Saf 2006;15:387-389
28. The Joint Commission. 2009 National Patient Safety Goals Hospital Program. www.jointcommission.org/NR/rdonlyres/31666E86-E7F4-423E-9BE8- F05BD1CB0AA8/0/HAP-NPSG.pdf (accessed 2008 Dec 23).
29. Degnan D, Merryfield D, Hultgren S. Reaching out to clinicians: implementation of a computerized alert system. J Healthc Qual 2004;26:26-30.
30. de Clercq PA, Blom JA, Hasman A, Korsten HHM. GASTON: an architecture for the acquisition and execution of clinical guideline-application tasks. Med Inform 2000;25:247-263 (Pubitemid 32046749)
31. Jha AK, Laguette J, Seger A, Bates DW. Can surveillance systems identify and avert adverse drug events? A prospective evaluation of a commercial application. J Am Med Inform Assoc 2008;15:647-653